ACTG A5001: AIDS CLINICAL TRIALS GROUP
LONGITUDINAL LINKED RANDOMIZED TRIALS (ALLRT) PROTOCOL
PUBLICATIONS AND PRESENTATIONS OF ALLRT DATA
2014 MANUSCRIPTS
Cillo AR, Krishnan S, McMahon D, Mitsuyasu RT, Para MF, Mellors JW. Impact of chemotherapy for
HIV-1 related lymphoma on residual viremia and cellular HIV-1 DNA in patients on suppressive
antiretroviral therapy. PLoS One 2014; 9(3):e92118.
Kalayjian R, Wu K, Evans S, Clifford D, Pallaki M, Currier J, Smurzynski M. Proteinuria is associated
with neurocognitive impairment in antiretroviral therapy treated HIV-infected individuals. In press (May
30, 2014) at Journal of Acquired Immune Deficiency Syndromes.
Kang M, Hollabaugh K, Pham V, Koletar SL, Wu K, Smurzynski M, Aberg JA. Virologic and serologic
outcomes of mono versus dual HBV therapy and characterization of HIV/HBV coinfection in a US
cohort. Journal of Acquired Immune Deficiency Syndromes 2014;66(2):172-80.
Tenorio AR, Zheng Y, Bosch RJ, Krishnan S, Rodriguez B, Hunt PW, Plants J, Seth A, Wilson CC,
Deeks SG, Lederman MM, Landay AL. Soluble markers of inflammation and coagulation but not T-cell
activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment.
Journal of Infectious Diseases 2014. [Epub ahead of print.]
Weinberg A, Bosch R, Bennett K, Tovar-Salazar A, Benson CA, Collier AC, Behm T, Zolopa A, Gulick
RM, Wohl D, Polsky B, Jacobson MA. Regulatory T cells and the risk of CMV end-organ disease in
AIDS patients. Journal of Acquired Immune Deficiency Syndromes 2014;66(1):25-32.
2014 Conference on Retroviruses and Opportunistic Infections, March 3 - March 6, 2014, Boston,
Massachusetts, USA. Abstracts available in Special Issue: Abstracts From the 2014 Conference on
Retroviruses and Opportunistic Infections. Topics in Antiviral Medicine 2014;22(e-1):34.
Atkinson B, Krishnan S, Collier AC. Low pre-ART CD4+ T cells, female sex, and atazanavir use
increase obesity risk after starting ART [CROI abstract 802].
Bruggeman LA, O'Toole JF, Ross MD, Madhavan SM, Smurzynski M, Wu K, Bosch RJ, Gupta S,
Pollak MR, Sedor JR, Kalayjian RC. Apolipoprotein L1 plasma levels do not correlate with
chronic kidney disease. Journal of the American Society of Nephrology 2014; 25(3):634-44.
Krishnan S, Bosch RJ, Rodriguez B, Hunt PW, Wilson C, Deeks SG, Lederman MM, Landay AL,
Tenorio AR. Correlates of inflammatory markers after one year of suppressive antiretroviral
treatment (ART) [CROI abstract 757].
Riddler SA, Aga E, Bosch R, Eron JJ, Gandhi R, Bastow B, Bedison M, Vagratian D, Mellors JW,
for the A5276s Protocol Team. Patterns of persistent viremia after 10 years of suppressive ART:
ACTG A5276s [CROI abstract 420].
Riddler SA, Aga E, Bosch R, Bastow B, Bedison M, Vagratian D, Eron JJ, Gandhi R, Mellors JW,
for the ACTG A5276s Protocol Team. Pre-ART HIV-1 RNA as well as on-treatment CD8 count and
CD4/CD8 ratio predict residual viremia on ART [CROI abstract 425LB].
2014 PRESENTATIONS
Riddler S. Findings from A5276s ([Residual Viremia Substudy of A5001 (ALLRT)]: Persistent Viremia
Cohort. ACTG Network Meeting, HIV Reservoirs and Viral Eradication Transformative Science Group
Plenary Session, June 25, 2014.
ALLRT and ALLRT-Related Publications and Presentations
Revised 07/03/14
Page 1 of 15
ACTG A5001: AIDS CLINICAL TRIALS GROUP
LONGITUDINAL LINKED RANDOMIZED TRIALS (ALLRT) PROTOCOL
PUBLICATIONS AND PRESENTATIONS OF ALLRT DATA
2013 MANUSCRIPTS
Abu-Raddad LJ, Barnabas RV, Janes H, Weiss HA, Kublin JG, Longini IM, Wasserheit JN. Have the explosive
HIV epidemics in sub-Saharan Africa been driven by higher community viral load? AIDS 2013;27(6):981-9.
Atkinson BE, Krishnan S, Cox G, Hulgan T, Collier AC. Anthropometric differences between HIV-infected
individuals prior to antiretroviral treatment and the general population from 1998-2007: The AIDS Clinical Trials
Group Longitudinal Linked Randomized Trials (ALLRT) cohort and the National Health and Nutrition
Examination Survey (NHANES). PLoS One 2013; 8(6):e65306.
Chang JJ, Woods M, Lindsay RJ, Doyle EH, Griesbeck M, Chan ES, Robbins GK, Bosch RJ, Altfeld M. Higher
expression of several interferon-stimulated genes in HIV-1-infected females after adjusting for the level of viral
replication. Journal of Infectious Diseases 2013; 208(5):830-8.
Chen H, Clifford DB, Deng L, Wu K, Lee AJ, Bosch R, Riddler SA, Ellis RJ, Evans SR. Peripheral
neuropathy in ART-experienced patients: prevalence and risk factors. Journal of NeuroVirology 2013;
19(6):557-64.
Hanna DB, Buchacz K, Gebo KA, Hessol NA, Horberg MA, Jacobson LP, Kirk GD, Kitahata MM,
Korthuis PT, Moore RD, Napravnik S, Patel P, Silverberg MJ, Sterling TR, Willig JH, Lau B, Althoff KN,
Crane HM, Collier AC, Samji H, Thorne JE, Gill MJ, Klein MB, Martin JN, Rodriguez B, Rourke SB,
Gange SJ; for the North American AIDS Cohort Collaboration on Research Design (NA-ACCORD) of the
International Epidemiologic Databases to Evaluate AIDS (IeDEA). Trends and disparities in
antiretroviral therapy initiation and virologic suppression among newly treatment-eligible HIV-infected
individuals in North America, 2001-2009. Clinical Infectious Disease 2013;56(8);1174-82.
Lok JJ, Hunt PW, Collier AC, Benson CA, Witt M, Luque AE, Deeks SG, Bosch RJ. The impact of age on the
prognostic capacity of CD8+ T-cell activation during suppressive antiretroviral therapy. AIDS 2013;
27(13):2101-10.
Overton ET, Kitch D, Benson CA, Hunt PW, Stein JH, Smurzynski M, Ribaudo HJ, Tebas P. The effect of statin
therapy in reducing the risk of serious non-AIDS-defining events and non-accidental death. Clinical Infectious
Diseases 2013; 56:1471-1479.
Smurzynski M, Wu K, Schouten JT, Lok JJ, Bosch RJ, Taiwo B, Johnson VA, Collier AC. Factors associated
with remaining on initial randomized efavirenz-containing regimens in the AIDS Clinical Trials Group. AIDS
2013; 27(12):1887-97.
Taiwo B, Hunt PW, Gandhi RT, Ellingson A, McKenna M, Jacobson JM, Gripshover B, Bosch RJ.
CD8+ T cell activation in HIV-1-infected patients experiencing transient low-level viremia during antiretroviral
therapy. Journal of Acquired Immune Deficiency Syndromes 2013; 63(1):101-104.
Zhang X, Hunt PW, Hammer SM, Cespedes MS, Patterson KB, Bosch RJ. Immune activation while on potent
antiretroviral therapy can predict subsequent CD4+ T cell increases through 15 years of treatment. HIV Clinical
Trials 2013; 14(2):61–67.
ALLRT and ALLRT-Related Publications and Presentations
Revised 07/03/14
Page 2 of 15
ACTG A5001: AIDS CLINICAL TRIALS GROUP
LONGITUDINAL LINKED RANDOMIZED TRIALS (ALLRT) PROTOCOL
PUBLICATIONS AND PRESENTATIONS OF ALLRT DATA
2013 ABSTRACTS
20th Conference on Retroviruses and Opportunistic Infections, March 3-6, 2013, Atlanta, GA.
Besson G, Lalama C, Bosch R, Gandhi R, Bedison A, Aga E, Riddler S, McMahon D, Hong F, Mellors J. HIV-1
DNA decay patterns in blood during more than a decade of suppressive ART: results from ACTG NWCS 360.
[LB Abstract D-1007) (NWCS 360)
Kalayjian R, Wu K, Evans S, Clifford D, Smurzynski M. Proteinuria is associated with neurocognitive
impairment in HIV infected subjects enrolled in the AIDS Clinical Trials Group Longitudinal Cohort Study
(ALLRT). Accepted for poster presentation. [Abstract F-114] (DACS 297)
Kang M, Hollabaugh K, Pham C, Koletar S, Wu K, Smurzynski M, Aberg J. Virologic and serologic outcomes in
HIV/HBV co-infected, HBV treatment naïve persons on mono- and dual- HBV therapy in ALLRT. Accepted for
poster presentation. [Abstract P-187] (NWCS 310)
Lok J, Hunt P, Deeks S, Collier A, Benson C, Witt M, Luque A, Bosch R. The prognostic capacity of CD8 T cell
activation during effective antiretroviral therapy is attenuated by age. Accepted for poster presentation.
[Abstract R-215] (DACS 286)
Riddler S, Aga E, Bosch R, Bedison A, Bastow B, Eron J, Gandhi R, Mellors J. Prevalence and patterns of
residual viremia in HIV+ patients on long-term suppressive antiretroviral therapy. Accepted for poster
presentation. [Abstract D-114] (A5276s)
Tenorio A, Zheng Y, Bosch R, Deeks S, Rodrigues B, Krishnan S, Hunt P, Wilson C, Lederman M, Landay A.
Soluble markers of inflammation & coagulation, but not T-cell activation, predict non-AIDS-defining events
during suppressive antiretroviral therapy. Accepted for poster and oral presentation. [Abstract R-206] (NWCS
329)
2013 PRESENTATIONS
Riddler, S. Update on A5276s, Residual Viremia Substudy of A5001 (ALLRT). ACTG Network Meeting, HIV
Reservoirs and Viral Eradication Transformative Science Group Think Tank, August 1, 2013.
ALLRT and ALLRT-Related Publications and Presentations
Revised 07/03/14
Page 3 of 15
ACTG A5001: AIDS CLINICAL TRIALS GROUP
LONGITUDINAL LINKED RANDOMIZED TRIALS (ALLRT) PROTOCOL
PUBLICATIONS AND PRESENTATIONS OF ALLRT DATA
2012 MANUSCRIPTS
Evans SR, Lee AJ, Ellis RJ, Chen H, Wu K, Bosch RJ, Clifford DB. HIV peripheral neuropathy progression:
protection with glucose-lowering drugs? Journal of Neurovirology 2012;18(5):428-33.
Holzinger ER, Grady B, Ritchie MD, Ribaudo HJ, Acosta EP, Morse GD, Gulick RM, Robbins GK, Clifford DB,
Daar ES, McLaren P, Haas DW. Genome-Wide association study of plasma efavirenz pharmacokinetics in
AIDS Clinical Trials Group protocols. Pharmacogenetics and Genomics 2012; 22: 858-67.
Krishnan S, Schouten JT, Atkinson B, Brown TT, Wohl DA, McComsey GA, Glesby MJ, Shikuma C, Haubrich
R, Tebas P, Campbell TB, Jacobson DL. Metabolic syndrome before and after initiation of antiretroviral therapy
in treatment-naive HIV-infected individuals. Journal of Acquired Immune Deficiency Syndromes
2012;1;61(3):381-89.
Tassiopoulos K, Landay A, Collier AC, Connick E, Deeks SG, Hunt PW, Lewis DE, Wilson CC, Bosch
RJ. CD28-negative CD4+ and CD8+ T-cells in ART-naïve HIV-infected adults enrolled in ACTG studies (DACS
266). Journal of Infectious Diseases 2012;205(11):1730-8.
Yin MT, Kendall MA, Wu X, Tassiopoulos K, Hochberg M, Huang JS, Glesby MJ, Bolivar H, McComsey GA.
Fractures after antiretroviral initiation. AIDS 2012;26(17):2175-84.
2012 ABSTRACTS
Atkinson B, Krishnan S, Collier A. Anthropometric differences between HIV-infected individuals prior to
antiretroviral treatment and the general population from 1998-2007: the ALLRT and the NHANES. 14th
International Workshop on Co-morbidities and Adverse Drug Reactions, July 19-21, 2012, Washington, DC.
Bruggeman LA, Ross MD, O'Toole J, Waikar S, Madhaven S, Smurzynski M, Bosch RJ, Gupta SK, Pollak M,
Sedor J, Kalayjian RC. Circulating apolipoprotein L1 levels and APOL1 genotype associations with chronic
kidney disease in HIV-1 infected African Americans. 9th International Podocyte Conference, April 22–25, 2012,
Miami, FL.
Cespedes M, Holzman R, McLaren P, Ostrer H, de Bakker P, Aberg J. Genome-wide association study of
cervical dysplasia risk in HIV+ women: ACTG DACS 268. [Abstract 898]. 19th Conference on Retroviruses and
Opportunistic Infections, March 3-8, 2012, Seattle, WA.
Chen H, Clifford D, Deng L, Wu K, Lee A, Bosch R, Ellis R, Evans S. Peripheral neuropathy in ARTexperienced patients: prevalence and risk factors. [Abstract E-120]. 19th Conference on Retroviruses and
Opportunistic Infections, March 3-8, 2012, Seattle, WA.
Cillo A, Krishnan S, McMahon D, Mitsuyasu R, Para M, Mellors J. Impact of chemotherapy for AIDS-related
lymphoma on residual viremia and cellular HIV-1 DNA in patients on suppressive antiretroviral therapy. (NWCS
334) [Abstract L-158]. 19th Conference on Retroviruses and Opportunistic Infections, March 3-8, 2012, Seattle,
WA.
Evans S, Lee A, Ellis R, Chen H, Wu K, Bosch R, Clifford D. Progression to symptoms of peripheral
neuropathy in HIV: suggested protection with use of glucose-lowering drugs. [Abstract E-161]. 19th
Conference on Retroviruses and Opportunistic Infections, March 3-8, 2012, Seattle, WA.
ALLRT and ALLRT-Related Publications and Presentations
Revised 07/03/14
Page 4 of 15
ACTG A5001: AIDS CLINICAL TRIALS GROUP
LONGITUDINAL LINKED RANDOMIZED TRIALS (ALLRT) PROTOCOL
PUBLICATIONS AND PRESENTATIONS OF ALLRT DATA
2012 ABSTRACTS (continued)
Kalayjian RC, Ross MD, O'Toole J, Waikar S, Madhaven S, Smurzynski M, Bosch RJ, Gupta SK, Pollak M,
Sedor J, Bruggeman LA. Associations between apolipoprotein L1 plasma levels and APOL1 genetic variants
with kidney disease in HIV-1 infected African Americans. XIX International AIDS Conference, July 22–27,
2012, Washington, DC.
Krishnan S, Schouten JT, Atkinson B, Brown TT, Wohl DA, Jacobson DL. Metabolic syndrome (MetS) status
after 96 weeks of antiretroviral therapy (ART) among HIV-infected individuals with MetS at ART initiation. 14th
International Workshop on Co-morbidities and Adverse Drug Reactions, July 19-21, 2012, Washington, DC.
Labo N, et al. Epidemiology of KSHV in HIV-1-infected persons in the era of combination antiretroviral therapy.
International Congress on Oncogenic Herpesviruses and Associated Diseases, August 1-4, 2012,
Philadelphia, PA.
Overton E, Kitch D, Tebas P, Hunt P, Ribaudo H, Smurzynski M, Stein J, Benson C. Effect of statin therapy on
reducing the risk of serious non-AIDS-defining events and non-accidental death in the AIDS Clinical Trials
Group Longitudinal Linked Randomized Trials (ALLRT) cohort. (DACS 280) [Abstract 124]. 19th Conference
on Retroviruses and Opportunistic Infections, March 3-8, 2012, Seattle, WA.
Taiwo B, Hunt P, Gandhi R, Ellingson A, McKenna M, Jacobson J, Bosch R. Immune activation in HIV-1
patients experiencing transiently detectable viremia during antiretroviral treatment. (DACS 279) [Abstract D267]. 19th Conference on Retroviruses and Opportunistic Infections, March 3-8, 2012, Seattle, WA.
Zhang X, Hunt P, Hammer S, Cespedes M, Patterson K, Bosch R. Immune activation while on potent
antiretroviral therapy can predict subsequent CD4+ T cell increases through 15 years of treatment. [Abstract
274]. 19th Conference on Retroviruses and Opportunistic Infections, March 3-8, 2012, Seattle, WA.
Zheng L, Taiwo B, Gandhi RT, Hunt PW, Bosch RJ. Factors associated with CD8+ T cell activation in HIV-1infected participants who have been on antiretroviral therapy for ≥96 weeks in ACTG studies. XIX International
AIDS Conference, July 22–27, 2012, Washington, DC.
2012 PRESENTATIONS
Lok JJ, Hunt PW, Deeks SG, Collier AC, Benson CA, Bosch RJ (invited talk). Careful selection of surrogate
outcomes with application to predictors of clinical events in HIV-positive patients. ICSA (International Chinese
Statistical Association) Applied Statistics Symposium, June 23-26, 2012, Boston, MA.
Riddler, S. Overview of A5276s: residual viremia substudy of A5001 (ALLRT). ACTG Network Meeting,
Plenary Session I, July 17, 2012.
Rodriguez R. Overview of data from NWCS 329: Activation, Inflammation and non-HIV related events in
antiretroviral treated and suppressed HIV+ persons. ACTG Network Meeting, End-Organ
Disease/Inflammation TSG Plenary Session, July 19, 2012.
Zheng S. Overview of data from DACS 285: Predictors of immune activation in virally suppressed participants.
ACTG Network Meeting, End-Organ Disease/Inflammation TSG Plenary Session, July 19, 2012.
ALLRT and ALLRT-Related Publications and Presentations
Revised 07/03/14
Page 5 of 15
ACTG A5001: AIDS CLINICAL TRIALS GROUP
LONGITUDINAL LINKED RANDOMIZED TRIALS (ALLRT) PROTOCOL
PUBLICATIONS AND PRESENTATIONS OF ALLRT DATA
2011 MANUSCRIPTS
Evans SR, Ellis RJ, Chen H, Yeh T, Lee AJ, Schifitto G, Wu K, Bosch RJ, McArthur JC, Simpson DM, Clifford
DB. Peripheral neuropathy in HIV: prevalence and risk factors. AIDS 2011;25(7):919-28.
Hoffman R et al. Baseline immune phenotypes and CD4+ T-lymphocyte responses to antiretroviral therapy in
younger versus older HIV-infected individuals. Journal of Clinical Immunology 2011; 31(5):873-81.
Krishnan S, Schouten JT, Jacobson DL, Benson CA, Collier AC, Koletar SL, Santana J, Sattler FR, Mitsuyasu
R, for the ACTG-ALLRT protocol team. Incidence of non-AIDS defining cancer in anti-retroviral treatment naïve
subjects after ART initiation: an ALLRT (ACTG Longitudinal Linked Randomized Trials) analysis. Oncology
2011;80:42-49.
Krishnan S, Wu K, Smurzynski M, Bosch RJ, Benson CA, Collier AC, Klebert MK, Feinberg J, Koletar SL: for
the ALLRT/A5001 team. Incidence rate of and factors associated with loss-to-follow-up in a longitudinal cohort
of anti-retroviral treated HIV-infected persons: an AIDS Clinical Trials Group Longitudinal Linked Randomized
Trials (ALLRT) analysis. HIV Clinical Trials 2011;12(4):190-200.
Lau B, Deeks S, Moore R, Eron J, et al. Missing data on the estimation of the prevalence of accumulated
human immunodeficiency virus drug resistance in patient started with antiretroviral drugs in North America.
American Journal of Epidemiology 2011;174(6):727-35.
Linas BP, Wang B, Smurzynski M, Losina E, Bosch RJ, Schackman BR, Rong J, Sax PE, Walensky RP,
Schouten J, Freedberg KA. The impact of HIV/HCV co-infection on healthcare utilization and disability: results
of the ACTG Longitudinal Linked Randomized Trials (ALLRT) cohort. Journal of Viral Hepatitis 2011; 18:50612.
Palermo B, Bosch RJ, Bennett K, Jacobson JM. Body mass index and CD4+ T-lymphocyte recovery in HIVinfected men with viral suppression on antiretroviral therapy. HIV Clinical Trials 2011;12(4):222-7.
Ribaudo HJ, Benson CA, Zheng Y, Koletar SL, Collier AC, Lok JJ, Smurzynski M, Bosch RJ, Bastow B,
Schouten JT; ACTG A5001/ALLRT Protocol Team. No risk of myocardial infarction associated with initial
antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT. Clinical
Infectious Diseases 2011;52(7):929-40.
Smurzynski M, Wu K, Letendre S, Robertson K, Bosch RJ, Clifford DB, Evans S, Collier AC, Taylor M, Ellis R.
Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort. AIDS
2011;25(3):357-65.
Swindells S, Jiang H, Mukherjee AL, Winters M, Bosch RJ, Katzenstein D, and AIDS Clinical Trials Group.
Lower CD4 cell count and higher virus load, but not antiretroviral drug resistance, are associated with AIDSdefining events and mortality: an ACTG Longitudinal Linked Randomized Trials (ALLRT) analysis. HIV Clinical
Trials 2011;12(2):79-88.
Taylor LE, Holubar M, Wu K, Bosch RJ, Wyles DL, Davis JA, Mayer KH, Sherman KE, Tashima KT. Incident
Hepatitis C virus infection among U.S. HIV-infected men enrolled in clinical trials. Clinical Infectious Diseases
2011;52:812-18.
ALLRT and ALLRT-Related Publications and Presentations
Revised 07/03/14
Page 6 of 15
ACTG A5001: AIDS CLINICAL TRIALS GROUP
LONGITUDINAL LINKED RANDOMIZED TRIALS (ALLRT) PROTOCOL
PUBLICATIONS AND PRESENTATIONS OF ALLRT DATA
2011 ABSTRACTS
Althoff K, Rebeiro P, Gill M John, Horberg M, Eron J, Napravnik S, Anastos K, Bosch R, Moore R, Gange S.
Trends in HIV viral load among adults in clinical care in the US and Canada, 1997-2007. [Poster 548]. 18th
Conference on Retroviruses and Opportunistic Infections, February 27-March 2, 2011, Boston, MA.
Hoffman R, Jamieson B, Bosch R, et al. Baseline immune phenotypes and CD4+ T-lymphocyte responses to
antiretroviral therapy in younger versus older HIV-infected individuals. 6th IAS Conference on HIV
Pathogenesis, Treatment and Prevention, July 17-20, 2011, Rome, Italy.
Liu H, Ribaudo H, Acosta EP. Pharmacogenetics of low plasma efavirenz (EFV) concentrations in AIDS clinical
trials group (ACTG) studies: analysis NWCS 301. 12th International Workshop on Clinical Pharmacology of
HIV Therapy [IWCPHT 11], April 13-15, 2011, Miami, FL.
Smurzynski M, Wu K, Bosch RJ, et al. Predictors of remaining on first-line randomized efavirenz-containing
regimens for up to five years in the AIDS Clinical Trials Group (ACTG): ACTG 384, A5095, A5142, A5202 and
the ACTG Longitudinal Linked Randomized Trials (ALLRT) long-term observational cohort [Abstract 32306].
49th Annual Meeting of the Infectious Diseases Society of America (IDSA), October 20 - 23, 2011, Boston, MA.
Tassiopoulos K, Landay A, Collier A, Connick E, Deeks S, Hunt P, Lewis D, Wilson C, Bosch R. CD28negative CD4+ and CD8+ T cells in ART-naive HIV-infected adults enrolled on ACTG studies: DACS 266.
[Abstract D-222]. 18th Conference on Retroviruses and Opportunistic Infections, February 27-March 2, 2011,
Boston, MA.
Weinberg A, Bosch R, Bennett K, Tovar-Salazar A, Benson C, Behm T, Zolopa A, Gulick R, Jacobson M.
CMV-specific and nonspecific regulatory T cells modulate the risk of CMV end-organ disease. [Abstract P-171].
18th Conference on Retroviruses and Opportunistic Infections, February 27-March 2, 2011, Boston, MA.
Yin M, Kendall M, Wu X, Tassiopoulos K, Huang J, Shane E, Hochberg M, McComsey G. Incidence and
predictors of fracture in HIV-infected individuals in the AIDS Clinical Trials Group Longitudinal Linked
Randomized Trials (ALLRT). [Abstract O-280]. 18th Conference on Retroviruses and Opportunistic Infections,
February 27-March 2, 2011, Boston, MA
2011 PRESENTATIONS
Evans SR, Ellis RJ, Chen H, Ye, Yeh TM, Lee AJ, Schifitto G, Wu K, Bosch RJ, McArthur JC, Simpson DM,
Clifford DB. Peripheral neuropathy in HIV: prevalence and risk factors. American Academies of Neurology,
April 9-16, 2011, Honolulu Hawaii.
Overton T. Initial findings from DACS 280 “The effect of statin therapy in reducing the risk of end-organ
disease and non-accidental death,” at the OpART Plenary, ACTG Meeting, June 2011.
ALLRT and ALLRT-Related Publications and Presentations
Revised 07/03/14
Page 7 of 15
ACTG A5001: AIDS CLINICAL TRIALS GROUP
LONGITUDINAL LINKED RANDOMIZED TRIALS (ALLRT) PROTOCOL
PUBLICATIONS AND PRESENTATIONS OF ALLRT DATA
2010 MANUSCRIPTS
Althoff KN, Gange SJ, Klein MB, Brooks JT, Hogg RS, Bosch RJ, Horberg MA, Saag MS, Kitahata MM, Justice
AC, Gebo KA, Eron JJ, Rourke SB, Gill MJ, Rodriguez B, Sterling TR, Calzavara LM, Deeks SG, Martin JN,
Rachlis AR, Napravnik S, Jacobson LP, Kirk GD, Collier AC, Benson CA, Silverberg MJ, Kushel M, Goedert
JJ, McKaig RG, Van Rompaey SE, Zhang J, Moore RD. Late presentation for human immunodeficiency virus
care in the United States and Canada. Clinical Infectious Diseases 2010;50(11):1512-1520.
Brown TT, Tassiopoulos K, Bosch RJ, Shikuma C, McComsey GA. Association between systemic
inflammation and incident diabetes in HIV-infected patients after initiation of antiretroviral therapy. Diabetes
Care 2010;33(10):2244-2249.
Cummins NW, Jiang W, Bren GD, Bosch RJ, Landay A, Deeks SG, Martin JN, Douek DC, Lederman MM,
Brenchley JM, Badley AD. Intracellular Casp8p41 content is inversely associated with CD4 T cell number.
Journal of Infectious Diseases 2010;202(3):386-91.
Lok JJ, Bosch RJ, Benson CA, Collier AC, Robbins GK, Shafer RW, Hughes MD; for the ALLRT team. Longterm increase in CD4+ T-cell counts during combination antiretroviral therapy for HIV-1 infection. AIDS
2010;24(12):1867-76.
Schacker TW, Bosch RJ, Bennett K, Pollard R, Robbins G, Collier AC, Gulick R, Spritzler J, Mildvan D.
Measurement of naïve CD4 cells reliably predicts potential for immune reconstitution in HIV. Journal of
Acquired Immune Deficiency Syndromes 2010; 54(1):59-62.
Smurzynski M, Wu K, Benson CA, Bosch RJ, Collier AC, Koletar SL. Relationship between CD4+ T-cell
counts/HIV-1 RNA plasma viral load and AIDS defining events among persons followed in the ACTG
Longitudinal Linked Randomized Trials (ALLRT) study. Smurzynski M., Wu K, Benson CA, Bosch RJ, Collier
AC, Koletar SL. Journal of Acquired Immune Deficiency Syndromes 2010; 55(1):117-27.
2010 ABSTRACT
Krishnan S, Wu K, Smurzynski M, Bosch R, Benson C, Collier A, Koletar S. Incidence rate and factors
associated with loss-to-follow-up in a longitudinal study of HIV-infected subjects receiving antiretrovirals: an
ALLRT analysis. 14th International Workshop on HIV Observational Databases, March 25- 27, 2010,
Barcelona, Spain.
2010 PRESENTATIONS
Gypsyamber D’Souza G, Jing Y, Strickler H, Silverberg M, Bosch R, Brooks JT, Engels E, Dubrow R, Hogg B,
Abraham AG. Cervical cancer epidemiology among HIV-infected women in North America. Abstract accepted
for oral presentation. 12th International Conference on Malignancies in AIDS and Other Acquired
Immunodeficiencies. (ICMAOI), April 26–27, 2010, Bethesda, MD.
Gypsyamber D’Souza G, Jing Y, Strickler H, Silverberg M, Bosch R, Brooks JT, Engels E, Dubrow R, Hogg B,
Abraham AG. Cervical cancer epidemiology among HIV-infected women in North America. Abstract accepted
for oral presentation. 26th International Papillomavirus Conference, July 3-8, 2010, Montreal, Canada.
ALLRT and ALLRT-Related Publications and Presentations
Revised 07/03/14
Page 8 of 15
ACTG A5001: AIDS CLINICAL TRIALS GROUP
LONGITUDINAL LINKED RANDOMIZED TRIALS (ALLRT) PROTOCOL
PUBLICATIONS AND PRESENTATIONS OF ALLRT DATA
2009 MANUSCRIPTS
Brown TT, Smurzynski M, Wu K, Bosch RJ, McComsey GA. Statin therapy and changes in hip circumference
among HIV-infected subjects in the ALLRT cohort. Antiviral Therapy 2009;14(6):853-8.
Clifford DB, Smurzynski M, Park LS, Yeh TM, Zhao Y, Blair L, Arens M, Evans SR. Effects of active HCV
replication on neurological status in HIV RNA virally suppressed patients. Neurology 2009; 73(4):309-14.
Deeks SG, Gange SJ, Kitahata MM, et al. for the North American AIDS Cohort Collaboration on Research and
Design. Trends in multi-drug failure and subsequent mortality among antiretroviral therapy-experienced HIVinfected patients in North America. Clinical Infectious Diseases 2009; 49(10):1582-90.
Gupta SK, Smurzynski M, Franceschini N, Bosch RJ, Szech LA, Kalayjian RC. The effects of HIV-1 viral
suppression and non-viral factors on quantitative proteinuria in the highly active antiretroviral era. Antiviral
Therapy 2009; 14(4):543-49.
Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC, Hogg RS, Deeks SG, Eron JJ,
Brooks JT, Rourke SB, Gill MJ, Bosch RJ, Martin JN, Klein MB, Jacobson LP, Rodriguez B, Sterling TR, Kirk
GD, Napravnik S, Rachlis AR, Calzavara LM, Horberg MA, Silverberg MJ, Gebo KA, Goedert JJ, Benson CA,
Collier AC, Van Rompaey SE, Crane HM, McKaig RG, Lau B, Freeman AM, Moore RD, for the NA-ACCORD
Investigators. Effect of early versus deferred antiretroviral therapy for HIV on survival. New England Journal of
Medicine 2009; 360:1815-1826.
2009 ABSTRACTS
Benson CA, Zheng E, Ribaudo H, Koletar SL, Collier A, Smurzynski M, Bosch R, Bastow B, Schouten J for the
ACTG A5001/ALLRT Protocol Team. No association of abacavir use with risk of myocardial infarction or
severe cardiovascular disease events: results from ACTG A5001 [abstract O-254]. 16th Conference on
Retroviruses and Opportunistic Infections, February 8-11, 2009, Montreal, Canada.
Brown TT, Tassiopoulos K, Shikuma C, McComsey GA. Higher markers of TNF activity 48 weeks after ARTinitiation are associated with incident diabetes mellitus in the ALLRT cohort: a nested case-control study.
[abstract] 11th International Workshop on Adverse Drug Reactions & Comorbidities in HIV, October 26-28,
2009, Philadelphia, PA.
Ellis RJ, Smurzynski M, Wu K, Bosch RJ, Robertson K, Evans S, Collier AC, Letendre S. Effects of CNS
antiretroviral distribution on neurocognitive impairment in the AIDS Clinical Trials Group (ACTG) Longitudinal
Linked Randomized Trials (ALLRT) study. 13th Annual Meeting of the American Neurological Association,
October 11-14, 2009, Baltimore, MD.
Evans SR, Clifford DB, Chen H, Schifitto G, Yeh T, Wu K, Bosch R, McArthur JC, Simpson DM, Ellis RJ. HIVassociated peripheral neuropathy in the HAART era: results from AIDS Clinical Trials Group (ACTG)
Longitudinal Linked Randomized Trials (ALLRT) protocol A5001 [abstract 462]. 16th Conference on
Retroviruses and Opportunistic Infections, February 8-11, 2009, Montreal, Canada.
Holubar M, Taylor LE, Wu K, Bosch RJ, Mayer KH, Tashima KT. Hepatitis C virus (HCV) antibody
seroconversion in a U.S. HIV-infected male clinical trials population [abstract LB14]. 60th Annual Meeting of
the American Association of the Study of Liver Diseases, October 30 - November 3, 2009, Boston, MA.
ALLRT and ALLRT-Related Publications and Presentations
Revised 07/03/14
Page 9 of 15
ACTG A5001: AIDS CLINICAL TRIALS GROUP
LONGITUDINAL LINKED RANDOMIZED TRIALS (ALLRT) PROTOCOL
PUBLICATIONS AND PRESENTATIONS OF ALLRT DATA
2009 ABSTRACTS (continued)
Krishnan S, Schouten J, Mitsuyasu R, for the ACTG-ALLRT protocol team. Incidence of non-AIDS defining
cancer (NADC) in anti-retroviral treatment (ART) naïve subjects after ART initiation: an ALLRT (ACTG
Longitudinal Linked Randomized Trials) analysis. 47th Annual Meeting of the Infectious Diseases Society of
America, October 29-November 1, 2009, Philadelphia, PA.
Linas BP, Wang B, Smurzynski M, Losina E, Bosch R, Schackman BR, Walensky RP, Schouten J, Freedberg
KA. The effect of hepatitis C virus co-infection on health care utilization among HIV-infected subjects: The
ACTG Longitudinal Linked Randomized Trials, Study 5001 [abstract Q-174]. 16th Conference on Retroviruses
and Opportunistic Infections, February 8-11, 2009, Montreal, Canada.
Lok JJ, Bosch RJ, Benson CA, Hughes MD. Long-term CD4 responses to potent antiretroviral treatment
(ART): an ALLRT (ACTG Longitudinally Linked Randomized Trial) database analysis. 13th International
Workshop on HIV Observational Databases, March 26-28, 2009, Lisbon, Portugal.
Swindells S, Jiang H, Mukherjee L, Winters M, Bosch R, Katzenstein D. Virologic drug resistance is not
associated with AIDS defining events or mortality: an ACTG Longitudinal Linked Randomized Trials (ALLRT)
analysis [abstract M-169]. 16th Conference on Retroviruses and Opportunistic Infections 2009, February 8-11,
2009, Montreal, Canada.
2009 PRESENTATIONS
Lok JJ, Bosch RJ. Inverse probability weighting methods in observational studies with application to long-term
CD4 outcomes in ACTG 384 and ALLRT. ACTG Meeting, June 2009.
Ribaudo H. The risk of myocardial infarction associated with initiating ART containing ABC versus no ABC over
3 and 6 years: results from ACTG A5001/ALLRT. ACTG Meeting, June 2009.
ALLRT and ALLRT-Related Publications and Presentations
Revised 07/03/14
Page 10 of 15
ACTG A5001: AIDS CLINICAL TRIALS GROUP
LONGITUDINAL LINKED RANDOMIZED TRIALS (ALLRT) PROTOCOL
PUBLICATIONS AND PRESENTATIONS OF ALLRT DATA
2008 MANUSCRIPTS
Kalayjian RC, Franceschini N, Gupta SK, Szczech LA, Mupere E, Bosch RJ, Smurzynski M, Albert JM.
Suppression of HIV-1 replication by antiretroviral therapy improves renal function in persons with low CD4 cells
and chronic kidney disease. AIDS 2008;22:481-487.
Smurzynski M, Collier AC, Koletar SL, Bosch RJ, Wu K, Bastow B, Benson CA. AIDS Clinical Trials Group
Longitudinal Linked Randomized Trials (ALLRT): rationale, design, and baseline characteristics. HIV Clinical
Trials 2008;9(4):269-281.
2008 ABSTRACTS
Barnabas RV, Abu-Raddad LJ, Janes H, Longini IM, Kublin JG, Wasserheit JN. Ecological analysis of global
variation in HIV viral load consistent with role for coinfection in regional differences in HIV epidemic trajectory
[poster P07-01]. AIDS Vaccine 2008, October 13-16, 2008, Cape Town, South Africa.
Deeks S and the NA-ACCORD. Trends in second virologic failure and predictors of subsequent mortality
among ART-experience patients: North American experience [abstract 41]. 15th Conference on Retroviruses
and Opportunistic Infections, February 3-6, 2008, Boston, MA.
Gupta S, Fransceschini N, Szczech L, Smurzynski M, Kalayjian R, and the AIDS Clinical Trials Group
Longitudinal Linked Randomized Study (ALLRT). The effects of HIV-1 viral suppression and non-viral factors
on clinically significant proteinuria in the HAART era [abstract 974]. 15th Conference on Retroviruses and
Opportunistic Infections, February 3-6, 2008, Boston, MA.
Koletar S, Smurzynski M, Wu K, Collier AC, Bosch RJ, Benson CA. AIDS-defining illnesses occurring in
treatment-experienced HIV-1-infected patients followed in the ACTG Longitudinal Linked Randomized Trials
(ALLRT) study [poster 1017]. 15th Conference on Retroviruses and Opportunistic Infections, February 3-6,
2008, Boston, MA.
Ribaudo HJ, Collier AC, Koletar S, Smurzynski M, Zheng Y, Bosch RJ, Benson CA. Risk factors associated
with serious non-AIDS-defining events (NADE) following treatment initiation in antiretroviral naïve individuals
enrolled in the AIDS Clinical Trials Group (ACTG) Longitudinal Linked Randomized Trials (ALLRT) study. 12th
International Workshop on HIV Observational Databases, March 27-30, 2008, Malaga, Spain.
Sterling T and the NA-ACCORD. TB after HAART initiation in the US and Canada [abstract 1001]. 15th
Conference on Retroviruses and Opportunistic Infections, February 3-6, 2008, Boston, MA.
2008 PRESENTATIONS
Benson CA. Non-AIDS defining events (NADE): mortality and morbidity including cardiovascular events. ACTG
Leadership Retreat, December 2008, Baltimore, MD.
Evans S. HIV-associated peripheral neuropathy in the HAART Era: preliminary results of an A5001 analysis.
ACTG meeting, June 24, 2008, Washington, DC.
Koletar S. AIDS-defining conditions: ALLRT cohort. ACTG Meeting, June 24, 2008, Washington, DC.
Robertson, KR. Neurocognitive examination: screening for cognitive problems in HIV. National Institute of
Mental Health Workshop, International Conference on AIDS and STI in Africa (ICASA) meeting. December
2008, Dakar, Senegal.
ALLRT and ALLRT-Related Publications and Presentations
Revised 07/03/14
Page 11 of 15
ACTG A5001: AIDS CLINICAL TRIALS GROUP
LONGITUDINAL LINKED RANDOMIZED TRIALS (ALLRT) PROTOCOL
PUBLICATIONS AND PRESENTATIONS OF ALLRT DATA
2007 MANUSCRIPTS
Bosch RJ, Bennett K, Collier AC, Zackin R, Benson CA for the AIDS Clinical Trials Group protocol A5001
team. Pre-treatment factors associated with 3 year (144 week) virologic and immunologic responses to potent
antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes 2007; 44(3):268-77.
Gange SJ, Kitahata MM, Saag MS, Bangsberg DR, Bosch RJ, Brooks JT, et al. Cohort profile: the North
American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). International Journal of
Epidemiology 2007; 36:294-301.
Kshirsagar SA, Blaschke TF, Sheiner LB, Krygowski M, Acosta EP, Verotta D. Improving data reliability using a
non-compliance detection method versus using pharmacokinetic criteria. Journal of Pharmacokinetics and
Pharmacodynamics 2007; 34(1):35-55.
Robertson KR, Smurzynski M, Parsons TD, Wu K, Bosch RJ, Wu J, McArthur JC, Collier AC, Evans SR, Ellis
RJ. The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS 2007;21(14):19151921.
Stapleton JT, Bennett K, Bosch RJ, Polgreen PM, Swindells S. Effect of antiretroviral therapy and hepatitis C
co-infection on changes in lipid levels in HIV-infected patients 48 weeks after initiation of therapy. HIV Clinical
Trials 2007; 8(6):429-436.
2007 ABSTRACTS
Clifford, David. The neurological effects of active hepatitis C virus replication in HIV-infected subjects enrolled
in ACTG 5001 who are virologically suppressed on HAART. 4th International AIDS Society Conference, July
22-25, 2007, Sydney, Australia.
Gupta SK, Komarow L, Gulick RM, Pollard RB, Robbins GK, Franceschini N, Szczech LA, Koletar SL,
Kalayjian RC. Proteinuria, creatinine clearance, and immune activation in HIV-infected subjects: a secondary
analysis of treatment-naïve studies ACTG 384, A5095, and A5001. 9th International Workshop on Adverse
Drug Reactions and Lipodystrophy in HIV, July 19-21, 2007, Sydney, Australia.
Kalayjian RC, Franceschini N, Gupta SK, Szczech LA, Mupere E, Smurzynski M, Albert JM. The association
between suppression of HIV-1 replication and glomerular filtration rates (GFR) among subjects on ACTG
A5001 (The ALLRT) [abstract N-241]. 14th Conference on Retroviruses and Opportunistic Infections, February
25-28, 2007, Los Angeles, CA.
Schacker T, Bosch R, Bennett K, Pollard R, Robbins G, Collier A, Gulick R, Spritzler J, Mildvan D.
Measurement of pretreatment peripheral blood naïve CD4+ T cell percent (nCD4%): a nomogram for
predicting CD4 increase on antiretroviral therapy (ART). 4th International AIDS Society Conference, July 2225, 2007, Sydney, Australia.
Smurzynski M. CD4 count, mortality and study discontinuation in the AIDS Clinical Trials Group (ACTG)
Longitudinal Linked Randomized Trials (ALLRT) Study [abstract 10C837]. 11th International Workshop on HIV
Observational Databases, March 22-25, 2007, Monte Carlo, Monaco.
2007 PRESENTATION
Clifford D. The effect of active HCV on neurocognitive function and neuropathy in HIV-infected subjects with
HIV viral suppression. ACTG Meeting, October 2007.
ALLRT and ALLRT-Related Publications and Presentations
Revised 07/03/14
Page 12 of 15
ACTG A5001: AIDS CLINICAL TRIALS GROUP
LONGITUDINAL LINKED RANDOMIZED TRIALS (ALLRT) PROTOCOL
PUBLICATIONS AND PRESENTATIONS OF ALLRT DATA
2006 MANUSCRIPTS
Haas DW, Geraghty D, Andersen J, D’Aquila R, Unutmaz D, Mar J, Benson CA, Landay A. Immunogenetics of
CD4 lymphocyte recovery during antiretroviral therapy: An Adult AIDS Clinical Trials Group study. Journal of
Infectious Diseases 2006; 194(8):1098-107.
Mrus J, Schackman B, Wu A, Freedberg KA, Tsevat J, Yi M, Zackin R. Variations in self-rated health among
patients with HIV infection. Quality of Life Research 2006;15:503-514.
2006 ABSTRACTS
Haas D, Motsinger A, Geraghty D, Ritchie M, D’Aquila R, Unutmaz D, Benson C, Landay A. Gene-gene
interactions and immune reconstitution during antiretroviral therapy: analysis NWCS 233 of ACTG Protocol
A5001. 13th Conference on Retroviruses and Opportunistic Infections, February 5-9, 2006, Denver, CO.
Robertson K, Wu K, Parsons T, Ellis RJ, Smurzynski M, Bosch R, Wu J, McArthur J, Collier A, Evans S.
Neurocognitive impairment in HIV-infected subjects on HAART: prevalence and associations. 13th Conference
on Retroviruses and Opportunistic Infections, February 5-9, 2006, Denver, CO.
Smurzynski M, Bosch RJ, Collier AC, Wu K, Benson CA. Patients followed in the Adult AIDS Clinical Trials
Group (ACTG) Longitudinal Linked Randomized Trials (ALLRT) A5001 study. HIV Cohort Database
Conference, March 2006, Madrid, Spain.
Smurzynski M, Collier AC, Koletar SL, Wu K, Bosch RJ, Benson CA. Opportunistic infections occurring after
initiation of randomized HAART regimens in treatment-naïve HIV-1-infected patients followed in the ACTG
Longitudinal Linked Randomized Trials (ALLRT) study. [poster 782]. 13th Conference on Retroviruses and
Opportunistic Infections, February 5-9, 2006, Denver, CO.
Stapleton JT, Swindells S. Hepatitis C infection is associated with decreased use of lipid-lowering therapy 48
weeks after initiation of combination antiretroviral therapy in the ACTG 5001 (ALLRT) cohort. 13th Conference
on Retroviruses and Opportunistic Infections, February 5-9, 2006, Denver, CO.
ALLRT and ALLRT-Related Publications and Presentations
Revised 07/03/14
Page 13 of 15
ACTG A5001: AIDS CLINICAL TRIALS GROUP
LONGITUDINAL LINKED RANDOMIZED TRIALS (ALLRT) PROTOCOL
PUBLICATIONS AND PRESENTATIONS OF ALLRT DATA
2005 MANUSCRIPT
Ellis RJ, Evans SR, Clifford DB, Moo LR, McArthur JC, Collier AC, Benson C, Bosch R, Simpson D,
Yiannoutsos CT, Yang Y, Robertson K; Neurological AIDS Research Consortium; AIDS Clinical Trials Group
Study Teams A5001 and A362. Clinical validation of the NeuroScreen. Journal of Neurovirology 2005; 11:50311.
2005 ABSTRACTS
Franceschini N, Kalayjian R, Smurzynski M, Gupta S. Clinical predictors of decreased renal function among
HIV-infected patients participating in the adult AIDS Clinical Trials Group Longitudinal Linked Randomized
Trials (ALLRT) study [poster F-PO1029]. American Society of Nephrology 38th Annual Renal Week Meeting,
November 8-13, 2005, Philadelphia, PA.
Haas DW, Geraghty D, Andersen J, D’Aquila R, Unutmaz D, Mar J, Benson CA, Landay A. Immunogenetics
and immune reconstitution during potent antiretroviral therapy: NWCS 233. 3rd International AIDS Society
Conference, July 24-27, 2005, Rio de Janeiro, Brazil.
2005 PRESENTATIONS
Benson C, Smurzynski M. Opportunistic infections occurring after initiation of randomized HAART regimens in
treatment-naïve HIV-1 infected patients followed in the ACTG longitudinal linked randomized trials (ALLRT)
study. ACTG Meeting, November 2005.
Bosch R, Bennett K, Collier AC, Zackin R, Benson CA (for the A5001 team). Pre-treatment factors associated
with 3-year (144 week) virologic and immunologic responses to antiretroviral therapy. ACTG Meeting,
November 2005.
Robertson K. Neurocognitive impairment in HIV-infected subjects on HAART - prevalence and associations.
AACTG Meeting, November 2005.
ALLRT and ALLRT-Related Publications and Presentations
Revised 07/03/14
Page 14 of 15
ACTG A5001: AIDS CLINICAL TRIALS GROUP
LONGITUDINAL LINKED RANDOMIZED TRIALS (ALLRT) PROTOCOL
PUBLICATIONS AND PRESENTATIONS OF ALLRT DATA
2004 ABSTRACT
Ellis RJ, Robertson K, McArthur J, Clifford D, Yang Y, Yiannoutsos C, Evans S. NARC 007: clinical validation
of the AACTG NeuroScreen [abstract G-43, poster 493]. 11th Conference on Retroviruses and Opportunistic
Infections, February 8-11, 2004, San Francisco, CA.
2004 PRESENTATION
Collier A. Characteristics of women in A5001. PACTG Obstetric/Woman’s Health Committee Interactive,
December 2004.
2003 MANUSCRIPT
Mrus JM, Yi MS, Freedberg KA, Wu AW, Zackin R, Gorski H, Tsevat J. Utilities derived from VAS analog scale
scores in patients with HIV/AIDS. Medical Decision Making 2003; 23:414-421.
2003 ABSTRACT
Benson CA, Collier A, Bosch R, Bennett K, Zackin R. Pre-treatment factors that predict responses to potent
antiretroviral therapy (ART): findings from AACTG A5001 (ALLRT). 10th Conference on Retroviruses &
Opportunistic Infections, February 10-14, 2003, Boston, MA.
2002 ABSTRACT
Mrus J, Yi M, Tsevat J, Wu A, Gorski H, Zackin R, Freedberg KA. Estimating quality of life and health utility
using Visual Analog Scale (VAS) scores in the Adult AIDS Clinical Trials Group Longitudinal Linked
Randomized Trials (ALLRT) cohort (A5001). XIV International AIDS Conference, July 7-12, 2002, Barcelona,
Spain.
2002 PRESENTATIONS
Benson C, Ellis R. Predictors of early response to potent ART in ART-naive ALLRT subjects (preliminary
results). AACTG meeting, July 2002.
Ellis R, Robertson KR, Yiannoutsos C, Evans S, Bosch RJ. Association of virologic suppression with the
prevalence and incidence of HIV-associated neurocognitive impairment and neuropathy in the ALLRT cohort.
AACTG meeting, July 2002.
2001 PRESENTATIONS
Ellis R (for the NARC 007 team). Association of HAART-induced virologic suppression with prevalence &
incidence of HIV neurocognitive impairment and distal sensory polyneuropathy in the ALLRT cohort. AACTG
meeting, July 2001.
Gorski H (for the ALLRT team). Demographic and baseline CD4/RNA data of ALLRT subjects. AACTG
meeting, July 2001.
ALLRT and ALLRT-Related Publications and Presentations
Revised 07/03/14
Page 15 of 15